Wyss Institute for Biologically Inspired Engineering, Boston, United States
Maia Norman
Wyss Institute for Biologically Inspired Engineering, Boston, United States; Tufts University School of Medicine, Boston, United States; Department of Pathology, Brigham and Women’s Hospital, Boston, United States
Roey Lazarovits
Wyss Institute for Biologically Inspired Engineering, Boston, United States
Wendy Trieu
Wyss Institute for Biologically Inspired Engineering, Boston, United States
Wyss Institute for Biologically Inspired Engineering, Boston, United States; Department of Pathology, Brigham and Women’s Hospital, Boston, United States; Harvard Medical School, Boston, United States
Extracellular vesicles (EVs) are released by all cells into biofluids and hold great promise as reservoirs of disease biomarkers. One of the main challenges in studying EVs is a lack of methods to quantify EVs that are sensitive enough and can differentiate EVs from similarly sized lipoproteins and protein aggregates. We demonstrate the use of ultrasensitive, single-molecule array (Simoa) assays for the quantification of EVs using three widely expressed transmembrane proteins: the tetraspanins CD9, CD63, and CD81. Using Simoa to measure these three EV markers, as well as albumin to measure protein contamination, we were able to compare the relative efficiency and purity of several commonly used EV isolation methods in plasma and cerebrospinal fluid (CSF): ultracentrifugation, precipitation, and size exclusion chromatography (SEC). We further used these assays, all on one platform, to improve SEC isolation from plasma and CSF. Our results highlight the utility of quantifying EV proteins using Simoa and provide a rapid framework for comparing and improving EV isolation methods from biofluids.